MAAT — Maat Pharma SA Share Price
Last trade - 00:00- €101.29m
- €91.06m
- €2.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.95 | ||
| Price to Tang. Book | 5.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 45.46 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.49% | ||
| Return on Equity | -83.41% | ||
| Operating Margin | -895.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | 0.97 | 1.43 | 2.23 | 3 | 3.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Maat Pharma SA is a France-based company, which is engaged into research and development in biotechnology sector. The Company specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 4th, 2014
- Public Since
- November 8th, 2021
- No. of Employees
- 50
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 11,616,306
- Address
- 70 Avenue Tony Garnier, LYON, 69007
- Web
- https://www.maatpharma.com/
- Phone
- +33 428291400
- Auditors
- Ernst & Young et Autres
Upcoming Events for MAAT
Similar to MAAT
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
As of Today at 19:13 UTC, shares in Maat Pharma SA are trading at €8.72. This share price information is delayed by 15 minutes.
Shares in Maat Pharma SA last closed at €8.72 and the price had moved by -8.21% over the past 365 days. In terms of relative price strength the Maat Pharma SA share price has underperformed the FTSE Global All Cap Index by -13.83% over the past year.
The overall consensus recommendation for Maat Pharma SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Maat Pharma SA does not currently pay a dividend.
Maat Pharma SA does not currently pay a dividend.
Maat Pharma SA does not currently pay a dividend.
To buy shares in Maat Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €8.72, shares in Maat Pharma SA had a market capitalisation of €101.29m.
Here are the trading details for Maat Pharma SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: MAAT
Based on an overall assessment of its quality, value and momentum Maat Pharma SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Maat Pharma SA is €15.80. That is 81.19% above the last closing price of €8.72.
Analysts covering Maat Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of -€2.37 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Maat Pharma SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +24.35%.
As of the last closing price of €8.72, shares in Maat Pharma SA were trading +22.11% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Maat Pharma SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €8.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Maat Pharma SA's management team is headed by:
- Jean-Marie Lefevre - NEC
- Herve Affagard - CEO
- Sian Crouzet - COO
- Savita Bernal - OTH
- John Weinberg - OTH